Home > News > Content

Current Situation And Development Trend Of Pharmaceutical Intermediates Abroad

Oct 02, 2020

For many years, pharmaceutical intermediates industry is the focus of investment and fierce competition in the world. In the past two decades, the pharmaceutical industry in the world has made unprecedented progress. By the end of the 1990s, the world pharmaceutical market has reached about 256 billion US dollars / A, and pesticide sales are about 23 billion dollars / A. As far as medicine is concerned, although biotechnology and genetic medicine have been developing continuously in recent ten years, important patent medicines have been constantly accepted by people. The development trend of the world pharmaceutical industry in the future is: high technology, high requirements, high speed and high concentration.

The main characteristics are the following five aspects: new drugs emerge in endlessly and varieties update is accelerated. For example, quinolones have been chemically synthesized over 20 000 compounds in the past 30 years. From 1962 to 1969, nalidixic acid, oxalinic acid and piromidic acid were successfully developed. It was replaced by flumequine and Pipemidic Acid from 1970 to 1977. Since 1978, fluoroquinolones have emerged and become the third generation of quinolones, such as ciprofloxacin, lomefloxacin and ofloxacin. They have broad antibacterial spectrum and stronger activity, and their curative effect is comparable to that of the third or fourth generation cephalosporins.

It is more and more difficult to create new drugs, and the management departments have higher and higher requirements on the efficacy and safety of drugs, which makes the investment in research and development increase dramatically. At the same time, new drug research and development is long-term, continuous, and has great risk. In order to adapt to the competition in the high-tech field, a huge amount of money is needed. In developed countries, the percentage of R & D expenditure in turnover (C / a ≈ 6.3%, C / b ≈ 17.7%) exceeds the turnover profit margin (D / a ≈ 5.2%). A-total turnover, b-pharmaceutical turnover, C-R & D fee, d-total profit (pharmaceutical industry, as a high-tech industry, needs high knowledge content. Pharmaceutical enterprises in various countries are constantly strengthening the strength of their research teams. For example, in American pharmaceutical enterprises, researchers account for 15% of the employees, and 26.7% of them have obtained doctor's degree or master's degree.

In order to occupy the market and strive to enter the best scale, pharmaceutical enterprises in developed countries have increased their economic strength and development and research capabilities through mergers and acquisitions. In France, for example, there were 1960 pharmaceutical enterprises in 1950, 880 in 1970, 392 in 1980, and 358 in 1989. For example, in 1990, there were 36 mergers and acquisitions of Japanese pharmaceutical companies, compared with 10 in 1979-1989. They all adopt the trinity of scientific research, production (including raw materials and preparations) and sales and scale production. They also focus on the future. Before the patent protection period of naproxen and ranitidine, which are expected to become bulk varieties, compete to find partners, develop new technical routes and production processes, develop production, reduce costs and expand sales, so as to be more conducive to participate in international competition.